SLGL
Sol-Gel Technologies Ltd.
stockNASDAQ
sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris ("acne") are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 69.45 | 2026-09-28 | +7.55% | -5.358 |
| 1M | 69.52 | 2026-09-04 | +7.44% | 0.645 |
| 3M | 74.12 | 2026-07-06 | +0.78% | 1.307 |
| 6M | 74.34 | 2026-04-06 | +0.48% | 0.927 |
| 1Y | 42.90 | 2025-10-06 | +74.11% | 0.835 |
| 2Y | 6.60 | 2024-10-04 | +1031.74% | — |
| 5Y | 97.80 | 2021-10-05 | -23.63% | 0.476 |
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) stock price today is $74.70, and today's volume is 12,392. SLGL is up 3.743% today. The 30 day average volume is 58,581. SLGL market cap is $244.55M with 3.27M shares outstanding.